BioXcel Therapeutics, Inc.
BTAI
$1.91
$0.000.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 98.00K | 120.00K | 168.00K | 366.00K | 214.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.00K | 120.00K | 168.00K | 366.00K | 214.00K |
| Cost of Revenue | 11.00K | 107.00K | 14.00K | 832.00K | 1.17M |
| Gross Profit | 87.00K | 13.00K | 154.00K | -466.00K | -956.00K |
| SG&A Expenses | 5.38M | 5.61M | 5.70M | 4.09M | 7.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.13M | 15.97M | 10.27M | 10.83M | 13.95M |
| Operating Income | -14.03M | -15.85M | -10.10M | -10.46M | -13.74M |
| Income Before Tax | -30.91M | -19.19M | -7.25M | -10.86M | -13.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.91M | -19.19M | -7.25M | -10.86M | -13.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.91M | -19.19M | -7.25M | -10.86M | -13.65M |
| EBIT | -14.03M | -15.85M | -10.10M | -10.46M | -13.74M |
| EBITDA | -13.96M | -15.78M | -10.02M | -10.38M | -13.66M |
| EPS Basic | -2.18 | -2.45 | -1.50 | -3.57 | -5.15 |
| Normalized Basic EPS | -1.35 | -1.53 | -0.94 | -2.23 | -2.85 |
| EPS Diluted | -2.18 | -2.45 | -1.50 | -3.57 | -5.15 |
| Normalized Diluted EPS | -1.35 | -1.53 | -0.94 | -2.23 | -2.85 |
| Average Basic Shares Outstanding | 14.20M | 7.84M | 4.83M | 3.04M | 2.65M |
| Average Diluted Shares Outstanding | 14.20M | 7.84M | 4.83M | 3.04M | 2.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |